Project Grant R44EY035584
Award Date
9/30/24
Completion Date
7/31/26
Dollars Obligated
$934K
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Springfield, IL 62711, USA
Similar Awards
This $440,000 Project Grant award from the National Eye Institute (NEI), under Federal Grant Program 93.867 (Vision Research), aims to develop a novel, disease-targeted anti-angiogenic therapy for treating wet age-related macular degeneration (AMD). The key product being developed is a neutralizing monoclonal antibody that targets a new, CNV-selective angiogenic factor discovered through the awardee's comparative ligandomics technology. This approach differs from currently approved anti-VEGF...
The U.S. National Eye Institute (NEI) awarded a $184,117 Project Grant (CFDA 93.867 - Vision Research) to Oakland University to determine the role of G-coupled protein receptors GPR31 and GPR39 in the pathogenesis of diabetic retinopathy. The project aims to investigate the affinities and substrate specificities of GPR31 and GPR39 for 12- and 15-HETE metabolites in retinal endothelial cells and Müller cells under normal and hyperglycemic conditions. It will also examine the effects of GPR31 or...
The National Eye Institute (NEI) awarded a $462,072 Project Grant (CFDA 93.867 - Vision Research) to Tufts Medical Center Parent, Inc. to study the metabolic basis of retinopathy of prematurity (ROP) and explore potential treatments using anaplerotic substrates. The project aims to investigate fatty acid metabolic exchanges between the liver and retina, and use genetic manipulations of fatty acid metabolic genes with adeno-associated viruses to prevent oxygen-induced retinopathy. The 5-year...
This $421,600 Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) will support research at Tufts Medical Center in Boston, MA to investigate the regulatory mechanisms governing retinal neovascularization. The research aims to delineate the role of chemokine signaling in recruiting peripheral immune cells to facilitate pathological vascular growth, as well as the role of microglial complement receptors in regulating neovessel regression. The project will utilize...
This $306,118 Project Grant awarded by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) aims to develop new technology and assays to test the efficacy and safety of investigational new drugs (INDs) for blinding diseases in functionally viable postmortem human donor eyes. The primary goals are to 1) establish ex vivo preclinical models for human ocular diseases and 2) develop a multichannel drug screening platform in light-responsive mouse and human retinas. This...
The National Eye Institute (NEI) awarded a $603,488 Project Grant (CFDA 93.867 - Vision Research) to Versiti Wisconsin, Inc. to conduct research on the role of the protein Rap1B in regulating inflammation and homeostasis in retinal endothelial cells. The project aims to: Assess how Rap1B influences the organization and signaling of lipid rafts containing the VEGF receptor VEGFR2, which is critical for maintaining endothelial health. Examine how Rap1B controls the balance between VEGFR2 and...
This $670,496 Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), supports research to investigate the paradoxical role of anti-VEGF therapy in subretinal fibrosis (SRF) associated with neovascular age-related macular degeneration (NAMD). The project aims to elucidate the mechanisms by which anti-VEGF therapy at different disease stages impacts SRF, and to develop novel dual anti-angiogenesis and anti-fibrosis therapies. The...
The National Eye Institute (NEI) under the Vision Research federal grant program (CFDA 93.867) awarded a $256,296 Project Grant (R21EY037019) to The General Hospital Corporation (Massachusetts General Hospital) to develop new optical coherence tomography angiography (OCTA) technology to improve the imaging of retinal microvasculature. The project aims to create a high-speed adaptive ranging OCTA system by leveraging advances in integrated photonics to expand the imaging depth range of OCTA,...
The National Eye Institute (NEI) awarded a $770,000 federal Project Grant under the NEI Vision Research program (CFDA 93.867) to the Augusta University Research Institute, Inc. (d/b/a Georgia Health Sciences) to identify novel mechanisms and develop new therapies for retinopathy of prematurity (ROP), a leading cause of preventable blindness in children. The key goals are to: 1) investigate the therapeutic efficacy of butyrate therapy in mouse models of ROP, 2) determine the relevance of...
This federal Project Grant award from the National Eye Institute (NEI), under the Vision Research program (CFDA 93.867), is funding the development of OPGX-RHO, a single-vector gene therapy for the treatment of autosomal-dominant retinitis pigmentosa (ADRP). The $882,971 award supports two key objectives: 1) completing chemistry, manufacturing, and controls for a clinical-grade batch of OPGX-RHO, including stability studies and device compatibility testing, and 2) conducting efficacy and...